Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment

To evaluate the effectiveness, safety and tolerability of Endostar (recombinant human endostatin) combined with AI chemotherapy in adjuvant treatment after radical resection of recurrent soft tissue sarcoma.

  • 0 views
  • 28 Jan, 2021
  • 1 location
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating …

cyclophosphamide
brain tumor
lomustine
tumor cells
neutrophil count
  • 119 views
  • 26 Mar, 2021
  • 133 locations
Cysteine-lowering Treatment With Mesna

The primary objective of this study is to determine the efficacy of the drug Mesna (Uromitexan) in healthy participants with overweight or obesity with respect to change in plasma concentrations

  • 0 views
  • 05 May, 2021
  • 1 location
IS-free Treg HaploHCT

>Radiation-Total Myeloid and Lymphoid Irradiation (TMLI Chemotherapy (Fludarabine, Thiotepa, Cyclophosphamide plus Mesna) Infusion of haplo Treg-enriched donor cells (experimental therapy

  • 0 views
  • 11 Feb, 2021
  • 1 location
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

purposes only. The chemotherapy drugs in this study (fludarabine, cyclophosphamide, and mesna) are commercially available and FDA approved. Up to 36 patients will take part in this study. All will

cyclophosphamide
lymphoma
oximetry
fludarabine
chemotherapy drug
  • 104 views
  • 24 Jan, 2021
  • 1 location
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.

  • 100 views
  • 22 Apr, 2021
  • 6 locations
Provision of TCR T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na ve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

This study seeks to examine treatment therapy that will reduced regimen-related toxicity and relapse while promoting rapid immune reconstitution with limited serious graft-versus-host-disease (GVHD) and also improve disease-free survival and quality of life. The investigators propose to evaluate the safety and efficacy of selective naive T-cell depleted (by TCR and …

cyclophosphamide
ejection fraction
myelomonocytic leukemia
fludarabine
hematologic malignancy
  • 189 views
  • 04 Feb, 2021
  • 1 location
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved and commercially …

filgrastim
combination chemotherapy
etoposide
carboplatin
ifosfamide
  • 3 views
  • 24 Jan, 2021
  • 1 location
Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide

This is a Phase II prospective trial to assess the rates of donor engraftment using reduced intensity conditioning (RIC) hematopoietic stem cell transplant (HSCT) and post-transplant cyclophosphamide (PTCy) for patients with primary immune deficiencies (PID), immune dysregulatory syndromes (IDS), and inherited bone marrow failure syndromes (IBMFS).

cyclophosphamide
immunoglobulin e
lad-1
granulomatous disease
hla-a
  • 0 views
  • 24 Jan, 2021
  • 1 location
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

Philadelphia chromosome (BCR-ABL1, Ph) is the most common genetic abnormality in acute lymphoblastic leukemia (ALL) and an independent prognostic risk factor. With the increase of age, the incidence of patients over 60 years old can reach 50%, whose 5-year overall survival rate was less than 20%. With the application of …

benzene ring
prednisone
philadelphia chromosome
tyrosine
imatinib
  • 0 views
  • 25 Jan, 2021
  • 3 locations